Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Inclusion Criteria: Inclusion criteria for enrolment * Pathologically documented, treatment naïve unresectable stage III NSCLC * Documented ALK-fusion, tested locally on tumour tissue by a validated method (DNA NGS, RNA NGS, FISH, IHC, or ctDNA) * ECOG Performance Status 0-1 * Age ≥18 years * Patient is a candidate to receive chemo-radiotherapy, as per investigator's assessment (including adequate haematological, renal and liver function as per local guidelines). * Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test within 5 weeks before enrolment. * Ability to comply with the trial protocol, in the investigator's judgment. * Written IC for trial participation must be signed and dated by the patient and the investigator prior to any trial-related intervention, including the submission of mandatory biomaterial. Eligibility criteria for randomisation Randomisation of eligible patients must occur within 8 weeks after the last radiotherapy fraction. * Completion of thoracic radiotherapy * Non-PD at restaging * Adequate haematological function * Adequate renal function * Adequate liver and pancreatic function * Women of childbearing potential, including women who had their last menstruation in the last 2 years, must have a negative urinary or serum pregnancy test before randomisation and should be repeated within 3 days before the first dose of brigatinib. * No radiation-pneu…